Stem Cell Therapies for Cardiovascular & Metabolic Disorders, 2019-2030

Stem Cell Therapies for Cardiovascular & Metabolic Disorders, 2019-2030

INTRODUCTION
Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. In fact, approximately one-third of the annual number of deaths across the globe are attributed to cardiovascular disorders. In the US, the annual economic burden associated with these disorders is estimated to be over USD 500 billion. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs are expected to be over USD 1 trillion by 2035. Despite considerable advances in healthcare, most of the currently available treatment options for cardiovascular disorders focus on palliative care and cannot actually repair damaged cardiac tissue. Although heart transplant is a viable option to treat complex cardiovascular conditions, the waiting time associated with this alternative is excruciatingly long.

Likewise, a significant proportion of the global population suffers from diabetes or some form of metabolism related clinical condition. As per IDF Diabetes Atlas, the treatment of diabetes and related complications incurred USD 727 billion in global healthcare expenditure in 2017. In 2017, it was estimated that 425 million individuals, between the ages 20 years to 79 years, were living with diabetes across the globe, and this number is expected to increase substantially in the foreseen future. Similar to cardiovascular diseases, most of the current treatment options for metabolic disorders are indicated for only controlling / managing disease related symptoms.

Advances in cell biology and regenerative medicine have led to the development of stem cell therapies that can potentially address several unmet needs and potentially offer a cure for various cardiovascular and metabolic disorders. The field of regenerative medicine has evolved substantially in the recent past; the first stem cell therapy, called Cellgram®-AMI (2011), was approved by the Ministry of Foods and Drug Safety of Korea, for the treatment of acute myocardial infarction. Presently, two other stem cell-based treatment options, namely HeartSheet® (heart failure, 2015) and Stempeucel® (critical limb ischemia, 2017), are commercially available for cardiovascular disorders. For metabolic disorders, most stem cell therapy candidates are still under development. However, there is one approved product, called Strimvelis™ for ADA-SCID (2016). Several stakeholders are engaged in efforts to advance the development of regenerative therapies for both cardiovascular and metabolic disorders. In fact, venture capital (VC) firms and government bodies are actively funding several such ongoing research initiatives.

SCOPE OF THE REPORT
The “Stem Cell Therapies for Cardiovascular & Metabolic Disorders, 2019-2030” report features an extensive study of the current market landscape and the future potential of stem cell therapies in treating the aforementioned clinical conditions. The study includes all stem cell therapies that are being developed for the treatment of cardiovascular and metabolic disorders. In addition, we have provided a list of stem cell therapies being developed for stroke, a condition associated with vasculature in the brain. Amongst other elements, the report features the following:

A detailed assessment of the current market landscape of stem cell therapies with respect to target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indications (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent, embryonic pluripotent and others), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary, subcutaneous implantation and surgical implantation).

An analysis highlighting the key unmet needs across cardiovascular and metabolic disorders, featuring insights generated from social media posts, recent scientific publications, patient blogs and the views of contemporary key opinion leaders as expressed on online platforms.

An overview of the focus areas of therapy developers, including an assessment of the existing opportunity for stem cell therapies across diverse therapeutic indications.

An insightful company competitiveness analysis featuring a three-dimensional bubble representation, highlighting the key players in this domain on the basis of the strength of their respective product portfolios, taking into consideration the number of therapies under development, phase of development of these therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.

An analysis of the partnerships that have been established in the domain in the period 2012-2018, covering R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreements, process development agreements, and other relevant deals.

An analysis of the investments made at various stages of development in companies that are focused in this area, including seed financing, venture capital financing, capital raised from IPOs / secondary offerings, debt financing and grants.

An analysis of contemporary peer-reviewed scientific research articles published during the period 2013-2018, highlighting the key focus areas of the ongoing research activity, in terms of therapeutic area, target disease indication, and source of cells.

Comprehensive profiles of approved and late stage clinical products; each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on recommended dose, price and manufacturing process (wherever available).

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate of the likely evolution of the market in the short to mid-term and long term, for the period 2019-2030. The report includes information on (potential) sales-based revenues generated by stem cell therapies that are currently marketed or are in late stages of development for the treatment of cardiovascular and metabolic disorders. Additionally, it presents details on the likely distribution of the current and forecasted opportunity across [A] target therapeutic areas (cardiovascular and metabolic), [B] target disease indications (myocardial ischemia, heart failure, critical limb ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other cardiovascular and metabolic disorders ), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and surgical implantation) and [G] key geographical regions (North America, Europe and Asia Pacific). To account for the uncertainties associated with the development of novel therapy products and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in this study were influenced by discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following individuals:
Michel Revel (Chief Scientist, Kadimastem) and Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem)
Xuejun H Parsons (Chief Executive Officer, Xcelthera)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

EXAMPLE HIGHLIGHTS
1. A review of content on both informal (150 patient blogs and over 900 social media posts) and formal (150 scientific articles) literary sources reveal the existence of several unmet needs within the treatment landscape of cardiovascular and metabolic disorders. Industry experts concur on this opinion as well, stating that one of the most pressing concerns is the need for alternative treatment options and novel therapeutic strategies that are more effective in treating the aforementioned types of clinical conditions.

2. Over the years, stem cell therapy has emerged as a promising treatment paradigm, offering a range of benefits, which include potential tissue regeneration capability, and favorable side effects profiles. Till date, four stem cell therapies have been approved for treating cardiovascular / metabolic disorders; these are (in order of approval year) Cellgram®-AMI (2011), HeartSheet® (2015), Strimvelis® (2016) and Stempeucel® (2017), indicated for the treatment of acute myocardial infarction, heart failure, ADA-SCID and critical limb ischemia, respectively.

3. More than 60 stem cell therapy candidates are being evaluated across different stages of development; over 40% of the pipeline candidates are presently in the mid to late-stages of development (phase II and above) and are likely to enter the market in the next 5-10 years. Examples of phase III therapy candidates include (in alphabetical order) aBMC (Cesca Therapeutics), BCDA-01 (BioCardia), CLBS14-NORDA (Caladrius Biosciences), MPC-150-IM (Mesoblast), OTL-200 (Orchard Therapeutics) and PLX-PAD (Pluristem Therapeutics).

4. Around 60% of pipeline stem cell therapy candidates are being developed for the treatment of cardiovascular disorders; of these, more than 70% target heart failure, myocardial infarction and critical limb ischemia. Within metabolic disorders, diabetes is the key target indication; in fact, close to 75% of stem cell therapies for metabolic disorders are being investigated for the treatment of diabetes. Examples include (in alphabetical order) apceth-201 (apceth Biopharma), hPSC (Kadimastem), Neo-islets (SymbioCellTech), SR-01 (Seraxis) and TARGETBCD (Evotec / Sanofi).

5. The niche, but evolving, stem cell therapies landscape is fragmented, featuring a mix of small. mid-sized and large companies. Some of the companies that have been established over the past 5-6 years include (in reverse chronological order), OiDE BetaRevive (part of Daiichi Sankyo) (2019), Semma Therapeutics (2015), Sigilon Therapeutics (2015), Longeveron (2014), and Xcelthera (2013). It is worth mentioning that the field has also witnessed significant contributions from several large firms, such as (in alphabetical order) AstraZeneca, Evotec, Novo Nordisk and Takeda Pharmaceutical. Most of the established players in this domain are presently evaluating their proprietary pipeline candidates in the preclinical stage.

6. Owing to the myriad of ethical concerns associated with the procurement and use of embryonic stem cells, over 80% of pipeline candidates are based on adult stem cells. Cells of the mesenchymal lineage represent the most commonly used type of adult stem cells. However, there are certain companies that claim to have developed ways to use embryonic stem cells for developing therapeutics; examples include Pluristem Therapeutics, ViaCyte, Tianhe Stem Cell Biotechnologies and Xcelthera.

7. It is worth noting that 25% of the strategic partnerships that were inked between various stakeholders in this field, during the period 2012-2018, were R&D agreements. Further, around 150 peer-reviewed articles related to stem cell therapies for cardiovascular and metabolic disorders were published between 2013 and 2018. This is indicative of the fact that research interest and efforts to innovate are presently high within this field.

8. Development efforts have been backed by various private and public investors, resulting in significant capital investments. In fact, since 2012, more than USD 2.0 billion (across 125 funding instances) has been invested in companies involved in the development of stem cell therapies for cardiovascular and metabolic disorders. In 2018 alone, 17 funding instances were reported, amounting to a total capital investment worth over USD 600 million.

9. The stem cell therapies market for cardiovascular and metabolic disorders is poised to experience rapid growth (at a CAGR of more than 10%) over the coming decade. The overall opportunity is anticipated to be distributed across the various types of stem cells, routes of administration and geographical regions. Owing to their favorable side effects profiles, autologous stem cell therapies are likely to capture the dominant market share (over 70%) during the period, 2019–2030. Although the currently approved therapies are available only in specific geographies, in the long term, North America and Europe are expected to hold the majority share as several late stage therapies are likely to receive approvals within these regions.

RESEARCH METHODOLOGY
The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:
Annual reports
Investor presentations
SEC filings
Industry databases
News releases from company websites
Government policy documents
Industry analysts’ views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

1.1. CHAPTER OUTLINES
Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the current scenario and the likely evolution of the stem cell therapies market for cardiovascular and metabolic disorders in the short to mid-term and long term.
Chapter 3 features a brief introduction to the basic concepts related to stem cell-based therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the diseases targeted by such therapies. Further, it provides details on cardiovascular and metabolic disorders, and the key indications that are being considered for treatment using stem cell therapies. Additionally, it highlights the challenges associated with stem cell therapies and provides brief insights on the anticipated future of such therapies, focusing on the treatment of cardiovascular and metabolic disorders.

Chapter 4 includes information on over 60 therapies that are currently approved / under development by industry players for the treatment of cardiovascular or metabolic disorders. It features a comprehensive analysis of pipeline therapies, highlighting the target therapeutic area (cardiovascular and metabolic), phase of development (approved, phase III, phase II, phase I and preclinical / discovery), target disease indication (Cardiovascular: heart failure, myocardial infarction, critical limb ischemia, angina, peripheral arterial / vascular diseases, myocardial ischemia, myocardial fibrosis, cardiomyopathy and coronary microvascular dysfunction; Metabolic: diabetes, mucopolysaccharidosis type III, ADA-SCID, obesity, mitochondrial disorders and metachromatic leukodystrophy), source of cells (autologous and allogenic), type of stem cells (adult multipotent, adult pluripotent, embryonic multipotent, embryonic pluripotent and others), stem cell lineage (bone marrow, peripheral blood, adipose tissue, cardiosphere, muscle, Wharton's jelly, umbilical cord, placenta, dental pulp, cord blood and pancreas), and route of administration (intramyocardial, intramuscular, intravenous, intracoronary, subcutaneous implantation and surgical implantation). Additionally, the chapter features information on over 40 therapies that are currently being developed by academic players. It also lists over 15 therapies that are being developed for the treatment of stroke.

Chapter 5 highlights the key unmet needs associated with stem cell therapies that are currently available / being developed for cardiovascular and metabolic disorders. The chapter provides detailed analysis of the various challenges and areas of concern, which were identified from views expressed by patients / experts across different platforms, such as social media posts, recent scientific publications, patient blogs, and the inputs of key opinion leaders. The chapter presents insightful word clouds, summarizing the opinions expressed across various public online portals.

Chapter 6 highlights the key target indications (myocardial infarction, heart failure, critical limb ischemia and diabetes) for which more than 7 stem cell therapies are currently under development. For each of these diseases, the chapter provides details on epidemiology, available treatment options, and the current market landscape of stem cell therapies (with respect to type of stem cell therapy, companies involved and phase of development).

Chapter 7 presents a three-dimensional bubble analysis highlighting the key companies (focused on cardiovascular and metabolic disorders) on the basis of the strength of their respective product portfolios, which takes into account the number of therapies under development, phase of development of candidate therapies, number of disease indications being targeted and geographical distribution of affiliated clinical trials.

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also discussed the different partnership models (including R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, manufacturing agreements, clinical trial agreement, process development agreement and other deals), and the most common forms of deals / agreements that have been established from 2012 to 2018.

Chapter 9 presents details on various investments and grants received by companies that are engaged in this domain. It includes a detailed analysis of the funding instances that have taken place during the period between 2012-2018, highlighting the growing interest of the venture capital community and other strategic investors within this market.

Chapter 10 provides a publication analysis, highlighting the recent trends in published literature related to stem cell therapies for cardiovascular and metabolic disorders. The chapter highlights the key focus areas of the ongoing research activity, in terms of type of therapeutic area, target disease indication, and source of cells.

Chapter 11 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase III) for cardiovascular disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 12 contains detailed profiles of drugs that are recently approved or are in advanced stages of clinical development (phase II or above) for metabolic disorders. Each profile features an overview of the therapy, its mechanism of action, history of development, current development status, key clinical trial results, details on administered dose, price and manufacturing process (wherever available).

Chapter 13 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It provides the market estimations for therapies that are either already approved or are in the late phases of clinical development (phase III), taking into consideration the target patient population, existing / future competition, likely adoption rates and the likely price. The chapter also presents a detailed segmentation of the opportunity on the basis of [A] target therapeutic area (cardiovascular and metabolic), [B] target disease indications (myocardial ischemia, heart failure, critical limb ischemia, diabetes, ADA-SCID, metachromatic leukodystrophy, and other cardiovascular and metabolic disorders), [C] type of stem cells (adult multipotent, adult pluripotent and embryonic multipotent), [D] source of cells (autologous and allogenic), [E] stem cell lineage (bone marrow, peripheral blood and others), [F] route of administration (intramyocardial, intracoronary, intramuscular, intravenous and surgical implantation) and [G] key geographical regions (North America, Europe and Asia Pacific).

Chapter 14 is a summary of the overall report. In this chapter, we have provided a list of key takeaways from the report, and expressed our independent opinion related to the research and analysis described in the previous chapters.

Chapter 15 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Michel Revel (Chief Scientist, Kadimastem), Galit Mazooz-Perlmuter (Business Development Manager, Kadimastem), and Xuejun H Parsons (Chief Executive Officer, Xcelthera).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 17 is an appendix, which provides the list of companies and organizations mentioned in the report.

LIST OF COMPANIES AND ORGANIZATIONS

The following companies / institutes / government bodies and organizations have been mentioned in this report.
1. 3P Biopharmaceuticals
2. 4BIO Capital
3. 6 Dimensions Capital
4. Advanced Stem Cell Rx
5. Agent Capital
6. Aldagen
7. Altaco XXI
8. Andalusian Initiative for Advanced Therapies
9. Ankara University
10. apceth Biopharma
11. ARCH Venture Partners
12. ArrowMark Partners
13. ASAP Ventures
14. Aspire Capital
15. Asset Management Partners
16. Assistance Publique - Hôpitaux de Paris
17. Athersys
18. Baillie Gifford
19. Bain Capital Life Sciences
20. Barts Health NHS Trust
21. Batipart
22. Beyond Type 1
23. BioCardia
24. BioLamina
25. BioRestorative Therapies
26. Boston Children’s Hospital
27. Boyalife Group
28. Bpifrance
29. Broadfin Capital
30. BTIG
31. Caladrius Biosciences
32. California Institute for Regenerative Medicine
33. Capricor Therapeutics
34. CardioCell
35. Celgene
36. Celixir
37. CellPraxis Bioengeneering
38. CellProthera
39. Celyad
40. Center for Cellular Technologies
41. Center for iPS Cell Research and Application
42. Cesca Therapeutics
43. Cha Bio&Diostech
44. Chinese Academy of Sciences
45. Cipla
46. Cognate BioServices
47. Colorado Center for Reproductive Medicine
48. Columbia University
49. Compass Biomedical
50. CORD:USE
51. CORESTEM
52. Cormorant Asset Management
53. Cowen Healthcare Investments
54. CRISPR Therapeutics
55. CureDuchenne Ventures
56. Cytopeutics
57. Cytori Therapeutics
58. Dai Nippon Printing
59. Daiichi Sankyo
60. Deerfield Management
61. Defymed
62. Driehaus Capital Management
63. DUKE National University Singapore Medical School
64. East Capital
65. East West Capital Partners
66. Eli Lilly
67. Evotec
68. Federal Research And Clinical Center
69. Flagship Pioneering
70. Foresite Capital
71. F-Prime Capital
72. Fuzhou General Hospital
73. General American Capital Partners
74. Ghost Tree Capital
75. GlaxoSmithKline
76. Global Cell Med
77. Gore
78. Great Ormond Street Hospital
79. Green Cross Health
80. GRI Fund
81. H.C. Wainwright
82. H2M Capital
83. Harvard Stem Cell Institute
84. Healios
85. Hercules Capital
86. Hospital La Paz Institute for Health Research
87. Hunton & Williams
88. Imperial College London
89. Innovative Cellular Therapeutics
90. Innovative Medical Management
91. Invetech
92. IRCCS San Raffaele
93. Israel Innovation Authority
94. Janssen Biotech
95. JDRF
96. Johann Wolfgang Goethe University Hospital
97. Johnson & Johnson
98. Johnson Trust
99. Juda Capital
100. Kadimastem
101. Kempen
102. Ladenburg Thalmann
103. Leerink Partners
104. Lifecell
105. Lincoln Park Capital
106. Lorem Vascular
107. LSK Partners
108. Ludwig Boltzmann Institute
109. M D Anderson Cancer Center
110. Magna Equities
111. Maryland Stem Cell Research Fund
112. McEwen Stem Cell Institute
113. Medical University of Silesia
114. Medical University of South Carolina
115. Medison Ventures
116. Medisun International
117. MedStar Heart & Vascular Institute
118. Medtronic
119. Medytox
120. Mesoblast
121. MidCap Financial
122. Miltenyi Biotec
123. Minovia Therapeutics
124. Moraga Biotechnology
125. MPM Capital
126. Nanjing Drum Tower Hospital
127. National Cardiovascular Center Harapan Kita Hospital
128. National Heart Centre Singapore
129. National Heart, Lung, and Blood Institute
130. National Institute of Diabetes and Digestive and Kidney Diseases
131. National Institutes of Health
132. National University of Ireland
133. Nile Therapeutics
134. Novartis
135. Novo Nordisk
136. Nuo Therapeutics
137. Okayama University
138. Orchard Therapeutics
139. ORI Healthcare Fund
140. Osaka University
141. Oxford BioMedica
142. Oxford Finance
143. Pavilion Capital
144. Peking University Aerospace Centre Hospital
145. Perceptive Advisors
146. PharmaCell
147. Pharmicell
148. Piper Jaffray
149. Pontifical Catholic University of Paraná
150. Postgraduate Institute of Medical Education and Research
151. Progenitor Cell Therapy
152. Queen Mary University of London
153. RA Capital Management
154. ReNeuron
155. RHEACELL
156. Rigshospitalet
157. Royal Brompton and Harefield NHS Foundation Trust
158. Royan Institute
159. RTW Investments
160. Sabby Capital
161. Sakakibara Heart Institute
162. Sanderling Ventures
163. Sanford Health
164. Sanofi
165. SC&H Capital
166. Sclnow Biotechnology
167. Semma Therapeutics
168. Seraxis
169. Shanghai 10th People's Hospital
170. Shanghai Biotechnology
171. Shavit Capital
172. Shire
173. Sigilon Therapeutics
174. Silicon Valley Bank
175. Sinopharm Capital
176. Sosei
177. South China Research Center for Stem Cell and Regenerative Medicine
178. Sphera Global Health Care
179. SPS Cardio
180. Stem Cell and Regenerative Medicine Institute
181. Stem cell unit, Van Hanh General Hospital
182. Stem Cells Arabia
183. Stempeutics Research
184. SymbioCellTech
185. Takeda Pharmaceutical
186. Tasly Pharmaceutical
187. Tel Aviv University
188. Temasek
189. Terumo BCT
190. The Champ Foundation
191. Thomson Medical Centre
192. Tianhe Stem Cell Biotechnologies
193. Tiger X Medical
194. TMC Life Sciences
195. Topstone Research
196. Toulouse University Hospital
197. TPG
198. U.S. Stem Cell
199. University Health Network
200. University Hospital, Clermont-Ferrand
201. University Hospital, Ostrava
202. University Medical Center, Utrecht
203. University Medical Centre Ljubljana
204. University of Bristol
205. University of California
206. University of Florence
207. University of Glasgow
208. University of Jordan
209. University of Kentucky
210. University of Manchester
211. University of Miami
212. University of Minnesota - Clinical and Translational Science Institute
213. University of Pennsylvania
214. University of Texas Health Science Center, Houston
215. University of Ulm
216. University of Utah
217. Venrock
218. Vericel
219. ViaCyte
220. Vinmec Research Institute of Stem Cell and Gene Technology
221. Viscofan BioEngineering
222. Wood Capital
223. Wu Capital
224. Xcelthera
225. Zheshang Venture Capital


1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3 Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Stem Cell Therapy
3.2.1. Classification of Stem Cell Therapies by Type of Cells
3.2.1.1. Embryonic Stem Cells
3.2.1.2. Adult Stem Cells
3.2.1.3. Induced Pluripotent Stem Cells
3.2.1.4. Cord Blood Stem Cells and Amniotic Fluid Stem Cells
3.2.2. Applications of Stem Cell Therapy
3.3. Overview of Cardiovascular Disorders
3.3.1. Key Indications being Investigated for Treatment with Stem Cells
3.4. Overview of Metabolic Disorders
3.4.1. Key Indications being Investigated for Treatment with Stem Cells
3.5. Administration of Stem Cell Therapies
3.6. Challenges Associated with Developing Stem Cell Therapies
3.7. Future Perspectives
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
4.2.1. Analysis by Target Therapeutic Area
4.2.2. Analysis by Phase of Development
4.2.3. Analysis by Source of Stem Cells
4.2.4. Analysis by Type of Stem Cells
4.2.5. Analysis by Stem Cell Lineage
4.2.6. Analysis by Route of Administration
4.2.7. Analysis by Target Indication
4.2.7.1. Cardiovascular Disorders
4.2.7.2. Metabolic Disorders
4.2.8. Key Developers
4.2.9. Heptagon Representation: Analysis by Target Indication and Phase of Development of Stem Cell Therapies
4.2.10. Grid Analysis: Target Indications, Phase of Development and Source of Stem Cells
4.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Landscape
4.3.1. Distribution by Focus Area
4.3.2. Distribution by Year of Establishment
4.3.3. Distribution by Size of Developer
4.3.4. Distribution by Geographical Location
4.3.5. Mapping Regional Activity
4.3.6. Logo Landscape: Analysis by Size and Target Therapeutic Area
4.4. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Additional Information
4.4.1. Information on Dosage
4.4.2. Information on Designations Awarded
4.4.3. Other Therapeutic Indications under Evaluation
4.5. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Contributions from Academia
4.6. Stem Cell Therapies for Stroke
5. UNMET NEED ANALYSIS
5.1. Chapter Overview
5.2. Unmet Needs Analysis in Stem Cell Therapies for Cardiovascular and Metabolic Disorders Market
5.2.1. Analysis of Data from Patient Blogs
5.2.1.1. Methodology
5.2.1.2. Key Insights: Cardiovascular Disorders
5.2.1.3. Key Insights: Metabolic Disorders
5.2.2. Analysis of Data from Published Literature
5.2.2.1. Methodology
5.2.2.2. Key Insights
5.2.2.2.1. Unmet Needs by Type of Indication
5.2.2.2.2. Unmet Needs by Stem Cell Lineage
5.2.3. Analysis of Data from Social Media Platforms
5.2.3.1. Methodology
5.2.3.2. Key Insights: Cardiovascular Disorders
5.2.3.3. Key Insights: Metabolic Disorders
5.2.4. Expert Opinions
5.2.4.1. Cardiovascular Disorders
5.2.4.1.1. Charles E Murry, Institute for Stem Cell and Regenerative Medicine
5.2.4.1.2. Stuart Conolly, McMaster University
5.2.4.1.3. Akshay Desai, Harvard Medical School; Sheryl Chow, Western University of Health Sciences College of Pharmacy; Scott Solomon, Harvard Medical School; Orly Vardeny, William S. Middleton Memorial VA Hospital
5.2.4.1.4. Naser M Ammash, Mayo Clinic and Joseph A Dearani, Mayo Clinic
5.2.4.1.5. Julie Anne Mitchell, Heart Foundation
5.2.4.1.6. Andre Terzic, Mayo Clinic and Atta Behfar, Mayo Clinic
5.2.4.2. Metabolic Disorders
5.2.4.2.1. Heather A Lau, Lysosomal Storage Disease Program, NYU Langone
5.2.4.2.2. Larry Hirsch, BD Diabetes Care
5.2.4.2.3. Michael Hirst, International Diabetes Federation; David Strain, University of Exeter Medical School in the UK; Xavier Cos, Sant Marti de Provençals Primary Care Centres
5.2.5. Summary of Key Unmet Needs in Cardiovascular and Metabolic Disorders
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Cardiovascular Disorders
6.2.1. Heart Failure
6.2.1.1. Overview
6.2.1.2. Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.3.1. Pharmacological Interventions
6.2.1.3.2. Therapeutic Devices
6.2.1.3.3. Surgery
6.2.1.4. Stem Cell Therapies for Heart Failure
6.2.2. Myocardial Infarction
6.2.2.1. Overview
6.2.2.2. Epidemiology
6.2.2.3. Current Treatment Landscape
6.2.2.3.1. Pharmacological Interventions
6.2.2.3.2. Surgery
6.2.2.4. Stem Cell Therapy for Myocardial Infarction
6.2.3. Critical Limb Ischemia
6.2.3.1. Overview
6.2.3.2. Epidemiology
6.2.3.3. Current Treatment Landscape
6.2.3.3.1. Pharmacological Interventions
6.2.3.3.2. Endovascular Treatments
6.2.3.3.3. Surgery
6.2.3.4. Stem Cell Therapy for Critical Limb Ischemia
6.3. Metabolic Disorders
6.3.1. Diabetes
6.3.1.1. Overview
6.3.1.2. Epidemiology
6.3.1.3. Current Treatment Landscape
6.3.1.3.1. Insulin Therapies
6.3.1.3.2. Non-Insulin Therapies
6.3.1.3.3. Surgery
6.3.1.4. Stem Cell Therapy for Diabetes
7. COMPANY COMPETITIVENESS ANALYSIS
7.1 Chapter Overview
7.2 Methodology
7.3 Assumptions and Key Parameters
7.4 Competitiveness Analysis
7.4.1. Companies Developing Stem Cell Therapies for Cardiovascular Disorders
7.4.1.1. Autologous Stem Cell Therapies
7.4.1.2. Allogenic Stem Cell Therapies
7.5.1. Company Developing Stem Cell Therapies for Metabolic Disorders
7.5.1.1. Autologous Stem Cell Therapies
7.5.1.2. Allogenic Stem Cell Therapies
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnerships
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Therapeutic Area
8.3.4. Regional Analysis
8.3.5. Most Active Players: Analysis by Number of Partnerships
9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding
9.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Funding and Investment Analysis
9.3.1. Analysis by Number of Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Number of Funding Instances and Amount Invested across Different Therapeutic Areas
9.3.5. Analysis by Number of Funding Instances and Amount Invested across Different Type of Stem Cells
9.3.6. Most Active Players
9.3.7. Most Active Investors
9.4. Concluding Remarks
10. PUBLICATION ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.3. Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Publications
10.3.1. Analysis by Year of Publication
10.3.2. Analysis by Key Journals
10.3.3. Analysis by Type of Study
10.3.4. Analysis by Type of Disorder
10.3.4.1. Cardiovascular Disorders
10.3.4.2. Metabolic Disorders
10.3.5. Analysis by Stem Cell Lineage
10.3.6. Analysis by Stem Cell Lineage and Focused Indication
10.3.7. Emerging Areas of Focus
11. STEM CELL THERAPIES FOR CARDIOVASCULAR DISORDERS: THERAPY PROFILES
11.1. Chapter Overview
11.2. Stempeucel® (Stempeutics Research)
11.2.1. Therapy Overview
11.2.2. History of Development
11.2.3. Technology Overview
11.2.4. Current Development Status
11.2.5. Key Clinical Trial Results
11.2.6. Dosing, Price and Manufacturing
11.3. Autologous Bone Marrow Concentrate (aBMC) (Cesca Therapeutics)
11.3.1. Therapy Overview
11.3.2. History of Development
11.3.3. Technology Overview
11.3.4. Current Development Status
11.3.5. Key Clinical Trial Results
11.4. BCDA-01 (BioCardia)
11.4.1. Therapy Overview
11.4.2. History of Development
11.4.3. Technology Overview
11.4.4. Current Development Status
11.4.5. Key Clinical Trial Results
11.5. BCDA-02 (BioCardia)
11.5.1. Therapy Overview
11.5.2. History of Development
11.5.3. Technology Overview
11.5.4. Current Development Status
11.5.5. Key Clinical Trial Results
11.6. CLBS14-NORDA (Caladrius Biosciences)
11.6.1. Therapy Overview
11.6.2. History of Development
11.6.3. Technology Overview
11.6.4. Current Development Status
11.6.5. Key Clinical Trial Results
11.7. MPC-150-IM (Mesoblast)
11.7.1. Therapy Overview
11.7.2. History of Development
11.7.3. Technology Overview
11.7.4. Current Development Status
11.7.5. Key Clinical Trial Results
11.8. PLX-PAD (Pluristem Therapeutics)
11.8.1. Therapy Overview
11.8.2. History of Development
11.8.3. Technology Overview
11.8.4. Current Development Status
11.8.5. Key Clinical Trial Results
12. STEM CELL THERAPIES FOR METABOLIC DISORDERS: THERAPY PROFILES
12.1. Chapter Overview
12.2. Strimvelis® (Orchard Therapeutics)
12.2.1. Therapy Overview
12.2.2. History of Development
12.2.3. Technology Overview
12.2.4. Current Development Status
12.2.5. Key Clinical Trial Results
12.2.6. Dosing, Price and Manufacturing
12.3. OTL-200 (Orchard Therapeutics)
12.3.1. Therapy Overview
12.3.2. History of Development
12.3.3. Technology Overview
12.3.4. Current Development Status
12.3.5. Key Clinical Trial Results
12.4. Stem Cell Therapy (Global Cell Med)
12.4.1. Therapy Overview
12.4.2. History of Development
12.4.3. Technology Overview
12.4.4. Current Development Status
12.4.5. Key Clinical Trial Results
12.5. LMSCs (Longeveron)
12.5.1. Therapy Overview
12.5.2. History of Development
12.5.3. Current Development Status
12.6. Stem Cell Educator Therapy (Tianhe Stem Cell Biotechnologies)
12.6.1. Therapy Overview
12.6.2. History of Development
12.6.3. Technology Overview
12.6.4. Current Development Status
12.6.5. Key Clinic Trial Results
13. MARKET FORECAST
13.1. Chapter Overview
13.2. Forecast Methodology and Key Assumptions
13.3. Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders, 2019-2030
13.3.1. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030
13.3.2. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.3.3. Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030
13.4. Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030
13.4.1. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030
13.4.2. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030
13.4.3. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030
13.4.4. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030
13.4.5. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030
13.4.6. Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030
13.4.7. Stem Cell Therapies Market for Cardiovascular Disorders: Myocardial Infarction, 2019-2030
13.4.7.1. Target Patient Population
13.4.7.2. Cellgram®-AMI (Pharmicell)
13.4.7.2.1. Sales Forecast
13.4.7.2.2. Sales Forecast by Geography
13.4.7.3. Cardiocell® (Cytopeutics)
13.4.7.3.1. Sales Forecast
13.4.7.3.2. Sales Forecast by Geography
13.4.8. Stem Cell Therapies Market for Cardiovascular Disorders: Heart Failure, 2019-2030
13.4.8.1. Target Patient Population
13.4.8.2. HeartSheet® (Terumo BCT)
13.4.8.2.1. Sales Forecast
13.4.8.2.2. Sales Forecast by Geography
13.4.8.3. BCDA-01 (BioCardia)
13.4.8.3.1. Sales Forecast
13.4.8.3.2. Sales Forecast by Geography
13.4.8.4. MPC-150-IM (Mesoblast)
13.4.8.4.1. Sales Forecast
13.4.8.4.2. Sales Forecast by Geography
13.4.8.5. Cardiocell® (Cytopeutics)
13.4.8.5.1. Sales Forecast
13.4.8.5.2. Sales Forecast by Geography
13.4.8.6. MyoCell® (U.S. Stem Cell)
13.4.8.6.1. Sales Forecast
13.4.8.6.2. Sales Forecast by Geography
13.4.9. Stem Cell Therapies Market for Cardiovascular Disorders: Critical Limb Ischemia, 2019-2030
13.4.9.1. Target Patient Population
13.4.9.2. Stempeucel® (Stempeutics Research)
13.4.9.2.1. Sales Forecast
13.4.9.2.2. Sales Forecast by Geography
13.4.9.3. aBMC (Cesca Therapeutics)
13.4.9.3.1. Sales Forecast
13.4.9.3.2. Sales Forecast by Geography
13.4.9.4. PLX-PAD (Pluristem Therapeutics)
13.4.9.4.1. Sales Forecast
13.4.9.4.2. Sales Forecast by Geography
13.4.9.5. Cardiocell® (Cytopeutics)
13.4.9.5.1. Sales Forecast
13.4.9.5.2. Sales Forecast by Geography
13.4.10. Stem Cell Therapies Market for Cardiovascular Disorders: Other Indications, 2019-2030
13.4.10.1. Target Patient Population
13.4.10.2. BCDA-02 (BioCardia)
13.4.10.2.1. Sales Forecast
13.4.10.2.2. Sales Forecast by Geography
13.4.10.3. CLBS14-NORDA (Caladrius Biosciences )
13.4.10.3.1. Sales Forecast
13.4.10.3.2. Sales Forecast by Geography
13.4.10.4. Cardiocell® (Cardiocell)
13.4.10.4.1. Sales Forecast
13.4.10.4.2. Sales Forecast by Geography
13.5. Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030
13.5.1. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030
13.5.2. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030
13.5.3. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030
13.5.4. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030
13.5.5. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cell Lineage, 2019-2030
13.5.6. Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030
13.5.7. Stem Cell Therapies Market for Metabolic Disorders: ADA-SCID, 2019-2030
13.5.7.1. Target Patient Population
13.5.7.2. Strimvelis® (Orchard Therapeutics)
13.5.7.2.1. Sales Forecast
13.5.7.2.2. Sales Forecast by Geography
13.5.8. Stem Cell Therapies Market for Metabolic Disorders: Metachromatic Leukodystrophy, 2019-2030
13.5.8.1. Target Patient Population
13.5.8.2. OTL-200 (Orchard Therapeutics)
13.5.8.2.1. Sales Forecast
13.5.8.2.2. Sales Forecast by Geography
13.5.9. Stem Cell Therapies Market for Metabolic Disorders: Type 1 Diabetes, 2019-2030
13.5.9.1. Target Patient Population
13.5.9.2. Unnamed Stem Cell Therapy by Global Cell Med
13.5.9.2.1. Sales Forecast
13.5.9.2.2. Sales Forecast by Geography
14. CONCLUSION
14.1. The Treatment Landscape of Cardiovascular and Metabolic Disorders is Characterized by Several Unmet Needs; Stem Cell Therapies have Demonstrated the Potential to Offer Viable and Lasting Therapeutic Effect
14.2. The Market Features a Promising Pipeline with Several Mid and Late Stage Product Therapies, which are Mostly based on Stem Cells Derived from Adults
14.3. The Fragmented Developer Landscape Includes Small, Mid-Sized and Established Players; the Majority of Stakeholders are Presently based in North America and Europe
14.4. The Heightened Pace of Research in this Field is Evident in Multiple R&D Agreements Inked and the Rise in Number of Scientific Articles Published in the Recent Years
14.5. Development Efforts in this Field have Garnered the Attention of Various Private and Public Investors, Resulting in Significant Capital Investments, which are Likely to Provide the Necessary Boost to the Market’s Future Growth
14.6. Given the Impending Approval of Multiple Late Stage Molecules, the Market is Poised to Grow at a Significant Pace in the Coming Years
15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Kadimastem
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Michel Revel, Chief Scientist and Galit Mazooz-Perlmuter, Business Development Manager
15.3. Xcelthera
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Xuejun H Parsons, Chief Executive Officer
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
LIST OF FIGURES
Figure 3.1 Stem Cell Therapies: Process of Therapy Development and Administration
Figure 3.2 Classification of Stem Cell Therapies by Type of Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Figure 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Figure 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Figure 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Figure 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Figure 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Figure 4.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Figure 4.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Figure 4.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Key Developers
Figure 4.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Indication and Phase of Development
Figure 4.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Grid Analysis
Figure 4.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Figure 4.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Figure 4.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Figure 4.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Figure 4.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size and Geographical Location of Developer
Figure 4.17 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Mapping Regional Activity
Figure 4.18 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Logo Landscape
Figure 4.19 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Designations Awarded to Stem Cell Therapies
Figure 5.1 Unmet Needs Analysis: Overview of Methodology
Figure 5.2 Unmet Needs in Cardiovascular Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.3 Unmet Needs in Metabolic Disorders: Word Cloud Analysis of Data from Patient Blogs
Figure 5.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Figure 5.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Figure 5.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Figure 5.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Figure 5.8 Unmet Needs in Stem Cell Therapies for Cardiovascular Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.9 Unmet Needs in Stem Cell Therapies for Metabolic Disorders: Word Cloud Analysis of Data from Social Media Tweets
Figure 5.10 Key Unmet Needs in Cardiovascular Disorders
Figure 5.11 Key Unmet Needs in Metabolic Disorders
Figure 6.1 Key Therapeutic Indications
Figure 6.2 Heart Failure: Types
Figure 6.3 Heart Failure: Symptoms
Figure 6.4 Heart Failure: Risk Factors
Figure 6.5 Heart Failure: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.6 Myocardial Infarction: Risk Factors
Figure 6.7 Myocardial Infarction: Distribution by Phase of Development and Type of Stem Cells
Figure 6.8 Critical Limb Ischemia: Symptoms
Figure 6.9 Critical Limb Ischemia: Risk Factors
Figure 6.10 Critical Limb Ischemia: Distribution of Stem Cell Therapies by Phase of Development and Type of Stem Cells
Figure 6.11 Diabetes: Risk Factors
Figure 6.12 Diabetes: Currently Available Non-Insulin Therapies
Figure 6.13 Diabetes: Distribution by Phase of Development and Type of Stem Cells
Figure 7.1 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Cardiovascular Disorders
Figure 7.2 Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Cardiovascular Disorders
Figure 7.3 Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Cardiovascular Disorders
Figure 7.4 Competitiveness Analysis of Companies Developing Stem Cell Therapies for Metabolic Disorders
Figure 7.5 Competitiveness Analysis of Companies Developing Autologous Stem Cell Therapies for Metabolic Disorders
Figure 7.6 Competitiveness Analysis of Companies Developing Allogenic Stem Cell Therapies for Metabolic Disorders
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Figure 8.5 Partnerships and Collaborations : Activity of Big Pharmaceutical Companies
Figure 8.6 Partnerships and Collaborations: Regional Distribution
Figure 8.7 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 8.8 Partnerships and Collaborations: Most Active Players
Figure 9.1 Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
Figure 9.2 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Figure 9.3 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Figure 9.4 Funding and Investments: Distribution by Type of Funding
Figure 9.5 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Figure 9.6 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Figure 9.7 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Figure 9.8 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Figure 9.9 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Figure 9.10 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Figure 9.11 Funding and Investments: Most Active Players
Figure 9.12 Funding and Investments: Most Active Investors
Figure 9.13 Funding and Investments Summary
Figure 10.1 Publications: Cumulative Trend by Year, 2013-2018
Figure 10.2 Publications: Most Popular Journals
Figure 10.3 Publications: Distribution by Type of Study
Figure 10.4 Publications: Distribution by Type of Disorder
Figure 10.5 Publications: Distribution by Type of Cardiovascular Disorders
Figure 10.6 Publications: Distribution by Type of Metabolic Disorders
Figure 10.7 Publications: Distribution by Stem Cell Lineage
Figure 10.8 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Figure 10.9 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Figure 10.10 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Figure 10.11 Publications: Emerging Areas
Figure 11.1 Stempeucel®: History of Development
Figure 11.2 Stempeucel®: Development / Manufacturing Process
Figure 11.3 aBMC by Cesca Therapeutics: History of Development
Figure 11.4 aBMC by Cesca Therapeutics: Development / Manufacturing Process
Figure 11.5 BCDA-01: History of Development
Figure 11.6 BCDA-01: Development / Manufacturing Process
Figure 11.7 BCDA-02: History of Development
Figure 11.8 BCDA-02: Development / Manufacturing Process
Figure 11.9 CLBS14-NORDA: History of Development
Figure 11.10 CLBS14-NORDA: Development / Manufacturing Process
Figure 11.11 MPC-150-IM: History of Development
Figure 11.12 MPC-150-IM: Development / Manufacturing Process
Figure 11.13 PLX-PAD: Mechanism of Action
Figure 11.14 PLX-PAD: History of Development
Figure 11.15 PLX-PAD: Development / Manufacturing Process
Figure 12.1 Strimvelis®: History of Development
Figure 12.2 Strimvelis®: Development / Manufacturing Process
Figure 12.3 OTL-200: Development / Manufacturing Process
Figure 12.4 Unnamed Stem Cell Therapy by Global Cell Med: Development / Manufacturing Process
Figure 12.5 Stem Cell Educator System: History of Development
Figure 12.6 Stem Cell Educator System: Development / Manufacturing Process
Figure 13.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.2 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, 2019-2030 (USD Million)
Figure 13.3 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.4 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.5 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.6 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.7 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.8 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.9 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.10 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.11 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.12 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.13 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.14 Cardiocell®: Sales Forecast for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.15 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Till 2030 (USD Million)
Figure 13.16 HeartSheet®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.17 HeartSheet®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.18 BCDA-01: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.19 BCDA-01: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.20 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.21 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.22 Cardiocell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.23 Cardiocell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.24 MyoCell®: Sales Forecast for Heart Failure, Till 2030 (USD Million)
Figure 13.25 MyoCell®: Sales Forecast by Geography for Heart Failure, Till 2030 (USD Million)
Figure 13.26 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.27 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.28 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.29 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.30 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.31 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.32 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.33 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Till 2030 (USD Million)
Figure 13.34 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.35 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.36 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.37 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.38 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.39 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Till 2030 (USD Million)
Figure 13.40 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, 2019-2030 (USD Million)
Figure 13.41 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, 2019-2030 (USD Million)
Figure 13.42 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, 2019-2030 (USD Million)
Figure 13.43 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, 2019-2030 (USD Million)
Figure 13.44 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, 2019-2030 (USD Million)
Figure 13.45 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, 2019-2030 (USD Million)
Figure 13.46 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, 2019-2030 (USD Million)
Figure 13.47 Strimvelis®: Sales Forecast for ADA-SCID, Till 2030 (USD Million)
Figure 13.48 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Till 2030 (USD Million)
Figure 13.49 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.50 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Till 2030 (USD Million)
Figure 13.51 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Till 2030 (USD Million)
Figure 13.52 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Till 2030 (USD Million)
Figure 14.1 Overall Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Conservative, Base and Optimistic Forecast Scenarios, 2020 and 2030 (USD Million)
LIST OF TABLES
Table 4.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Marketed and Development Pipeline (Industry Players)
Table 4.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Developer Overview
Table 4.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Dose of Stem Cell Therapies
Table 4.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Information on Designations Awarded to Stem Cell Therapies
Table 4.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Other Indications Under Evaluation
Table 4.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Pipeline Overview (Academic Players)
Table 4.7 Stem Cell Therapies for Stroke
Table 5.1 Unmet Needs in Stem Cell Therapies for Cardiovascular and Metabolic Disorders: List of Blog Portals
Table 6.1 Heart Failure: List of Marketed Drugs
Table 6.2 Heart Failure: List of Stem Cell Therapies
Table 6.3 Myocardial Infarction: List of Marketed Drugs
Table 6.4 Myocardial Infarction: List of Stem Cell Therapies
Table 6.5 Peripheral Arterial Diseases: List of Marketed Drugs
Table 6.6 Critical Limb Ischemia: List of Stem Cell Therapies
Table 6.7 Diabetes: Current Treatment Landscape
Table 6.8 Diabetes: List of Stem Cell Therapies
Table 8.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Partnerships and Collaborations, 2012-2018
Table 9.1 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Funding and Investments, 2012-2018
Table 9.2 Funding and Investment Analysis: Summary of Investments
Table 10.1 Stem Cell Therapy for Cardiovascular and Metabolic Disorders: List of Publications, 2013-2018
Table 11.1 Stempeutics: Clinical Trials
Table 11.2 aBMC by Cesca Therapeutics: Clinical Trials
Table 11.3 BCDA-01: Clinical Trials
Table 11.4 BCDA-02: Clinical Trials
Table 11.5 CLBS14-NORDA: Clinical Trials
Table 11.6 MPC-150-IM: Clinical Trials
Table 11.7 PLX-PAD: Clinical Trials
Table 12.1 Strimvelis: Clinical Trials
Table 12.2 Stem Cell Therapy by Global Cell Med: Clinical Trials
Table 12.3 LMSCs: Clinical Trials
Table 12.4 Stem Cell Educator Therapy: Clinical Trials
Table 15.1 Kadimastem: Key Highlights
Table 15.2 Xcelthera: Key Highlights
Table 16.1 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Target Therapeutic Area
Table 16.2 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Phase of Development
Table 16.3 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells
Table 16.4 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Stem Cells
Table 16.5 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Stem Cell Lineage
Table 16.6 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Route of Administration
Table 16.7 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Cardiovascular Disorder
Table 16.8 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Type of Metabolic Disorder
Table 16.9 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Focus Area of Developer
Table 16.10 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Year of Establishment of Developer
Table 16.11 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Size of Developer
Table 16.12 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Distribution by Geographical Location of Developer
Table 16.13 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature
Table 16.14 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type and Year
Table 16.15 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Type of Indication
Table 16.16 Stem Cell Therapies for Cardiovascular and Metabolic Disorders: Unmet Needs Highlighted in Published Literature by Stem Cell Lineage
Table 16.17 Partnerships and Collaborations: Cumulative Trend by Year, 2012-2018
Table 16.18 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.19 Partnerships and Collaborations: Distribution by Year of Partnership and Therapeutic Area
Table 16.20 Partnerships and Collaborations: Distribution by Type of Partnership, 2012-2015 and Post 2015
Table 16.21 Partnerships and Collaborations: Regional Distribution
Table 16.22 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 16.23 Funding and Investments: Distribution by Type of Funding and Year, 2012-2018
Table 16.24 Funding and Investments: Cumulative Number of Instances by Year, 2012-2018
Table 16.25 Funding and Investments: Cumulative Amount Invested by Year, 2012-2018 (USD Million)
Table 16.26 Funding and Investments: Distribution by Type of Funding
Table 16.27 Funding and Investments: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 16.28 Funding and Investments: Distribution of Number of Funding Instances by Year across Major Therapeutic Areas, 2012-2018
Table 16.29 Funding and Investments: Amount Invested by Year across Major Therapeutic Areas, 2012-2018
Table 16.30 Funding and Investments: Distribution of Number of Instances by Type of Funding, 2012-2015 and Post 2015
Table 16.31 Funding and Investments: Amount Invested by Type of Funding, 2012-2015 and Post 2015
Table 16.32 Funding and Investments: Amount Invested by Year of Investments in Various Type of Stem Cells, 2012-2018
Table 16.33 Publications: Cumulative Trend by Year, 2013-2018
Table 16.34 Publications: Distribution by Type of Study
Table 16.35 Publications: Distribution by Type of Disorder
Table 16.36 Publications: Distribution by Type of Cardiovascular Disorders
Table 16.37 Publications: Distribution by Type of Metabolic Disorders
Table 16.38 Publications: Distribution by Stem Cell Lineage
Table 16.39 Publications: Distribution of Articles Focused on Bone Marrow Derived Stem Cells by Indication
Table 16.40 Publications: Distribution of Articles Focused on Cardiosphere Derived Stem Cells by Indication
Table 16.41 Publications: Distribution of Articles Focused on Adipose Derived Stem Cells by Indication
Table 16.42 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.43 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.44 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.45 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Conservative Scenario, 2019-2030 (USD Million)
Table 16.46 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Base Scenario, 2019-2030 (USD Million)
Table 16.47 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Therapeutic Area, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.48 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.49 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.50 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.51 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.52 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.53 Stem Cell Therapies Market for Cardiovascular and Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.54 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.55 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.56 Stem Cell Therapies Market for Cardiovascular Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.57 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.58 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.59 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.60 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.61 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.62 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.63 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.64 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.65 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.66 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.67 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.68 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.69 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.70 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.71 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.72 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.73 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.74 Stem Cell Therapies Market for Cardiovascular Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.75 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.76 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.77 Cellgram®-AMI: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.78 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.79 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.80 Cellgram®-AMI: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.81 Cardiocell®: Sales Forecast for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.82 Cardiocell®: Sales Forecast for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.83 Cardiocell®: Sales Forecast for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.84 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Conservative Scenario, Till 2030 (USD Million)
Table 16.85 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Base Scenario, Till 2030 (USD Million)
Table 16.86 Cardiocell®: Sales Forecast by Geography for Myocardial Infarction, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.87 HeartSheet®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.88 HeartSheet®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.89 HeartSheet®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.90 HeartSheet®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.91 HeartSheet®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.92 HeartSheet®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.93 BCDA-01: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.94 BCDA-01: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.95 BCDA-01: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.96 BCDA-01: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.97 BCDA-01: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.98 BCDA-01: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.99 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.100 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.101 MPC-150-IM (Rexlemestrocel-L): Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.102 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.103 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.104 MPC-150-IM (Rexlemestrocel-L): Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.105 Cardiocell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.106 Cardiocell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.107 Cardiocell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.108 Cardiocell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario Till 2030 (USD Million)
Table 16.109 Cardiocell®: Sales Forecast by Geography for Heart Failure, Base Scenario Till 2030 (USD Million)
Table 16.110 Cardiocell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario Till 2030 (USD Million)
Table 16.111 MyoCell®: Sales Forecast for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.112 MyoCell®: Sales Forecast for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.113 MyoCell®: Sales Forecast for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.114 MyoCell®: Sales Forecast by Geography for Heart Failure, Conservative Scenario, Till 2030 (USD Million)
Table 16.115 MyoCell®: Sales Forecast by Geography for Heart Failure, Base Scenario, Till 2030 (USD Million)
Table 16.116 MyoCell®: Sales Forecast by Geography for Heart Failure, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.117 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.118 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.119 Stempeucel®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.120 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.121 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.122 Stempeucel®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.123 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.124 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.125 aBMC by Cesca Therapeutics: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.126 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.127 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.128 aBMC by Cesca Therapeutics: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.129 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.130 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.131 PLX-PAD: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.132 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.133 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.134 PLX-PAD: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.135 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.136 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.137 Cardiocell®: Sales Forecast for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.138 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Conservative Scenario, Till 2030 (USD Million)
Table 16.139 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Base Scenario, Till 2030 (USD Million)
Table 16.140 Cardiocell®: Sales Forecast by Geography for Critical Limb Ischemia, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.141 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.142 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.143 BCDA-02: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.144 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.145 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, base Scenario, Till 2030 (USD Million)
Table 16.146 BCDA-02: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.147 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.148 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.149 CLBS14-NORDA: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.150 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.151 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.152 CLBS14-NORDA: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.153 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.154 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.155 Cardiocell®: Sales Forecast for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.156 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Conservative Scenario, Till 2030 (USD Million)
Table 16.157 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Base Scenario, Till 2030 (USD Million)
Table 16.158 Cardiocell®: Sales Forecast by Geography for Other Cardiovascular Indications, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.159 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Conservative Scenario, 2019-2030 (USD Million)
Table 16.160 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Base Scenario, 2019-2030 (USD Million)
Table 16.161 Stem Cell Therapies Market for Metabolic Disorders: Overall Market, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.162 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Conservative Scenario, 2019-2030 (USD Million)
Table 16.163 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Base Scenario, 2019-2030 (USD Million)
Table 16.164 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Indication, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.165 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.166 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.167 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Source of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.168 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Conservative Scenario, 2019-2030 (USD Million)
Table 16.169 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Base Scenario, 2019-2030 (USD Million)
Table 16.170 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Route of Administration, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.171 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Conservative Scenario, 2019-2030 (USD Million)
Table 16.172 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Base Scenario, 2019-2030 (USD Million)
Table 16.173 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Type of Stem Cells, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.174 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Conservative Scenario, 2019-2030 (USD Million)
Table 16.175 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Base Scenario, 2019-2030 (USD Million)
Table 16.176 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Stem Cell Lineage, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.177 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Conservative Scenario, 2019-2030 (USD Million)
Table 16.178 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Base Scenario, 2019-2030 (USD Million)
Table 16.179 Stem Cell Therapies Market for Metabolic Disorders: Distribution by Geography, Opportunistic Scenario, 2019-2030 (USD Million)
Table 16.180 Strimvelis®: Sales Forecast for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.181 Strimvelis®: Sales Forecast for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.182 Strimvelis®: Sales Forecast for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.183 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Conservative Scenario, Till 2030 (USD Million)
Table 16.184 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Base Scenario, Till 2030 (USD Million)
Table 16.185 Strimvelis®: Sales Forecast by Geography for ADA-SCID, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.186 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.187 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.188 OTL-200: Sales Forecast for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.189 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Conservative Scenario, Till 2030 (USD Million)
Table 16.190 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Base Scenario, Till 2030 (USD Million)
Table 16.191 OTL-200: Sales Forecast by Geography for Metachromatic Leukodystrophy, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.192 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.193 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.194 Unnamed Stem Cell Therapy by Global Cell Med: Sales Forecast for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)
Table 16.195 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Conservative Scenario, Till 2030 (USD Million)
Table 16.196 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Base Scenario, Till 2030 (USD Million)
Table 16.197 Unnamed Stem Cell Therapy by Global Cell Med : Sales Forecast by Geography for Type 1 Diabetes, Opportunistic Scenario, Till 2030 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook